Skip to main content
Log in

Sisomicin therapy of serious gram-negative infections

Sisomicin-Therapie bei schweren gramnegativen Infektionen

  • III. Klinische Erfahrungen
  • Published:
Infection Aims and scope Submit manuscript

Summary

Sisomicin, a dehydrogenated gentamicin C1a derivative, was employed to treat serious gram-negative infections. A satisfactory clinical response was obtained in 79 % of 34 episodes of infection. Response was good even in the presence of preexisting renal or hepatic disease and in spite of concomitant use of immunosuppressive agents. Pseudomonas and Serratia urinary tract infections responded well with failure occurring only in patients with marked structural abnormalities. Pulmonary infections showed good clinical response in spite of failure to eliminate the organism from the sputum of patients with extensive underlying pulmonary disease. Although serious nephrotoxicity was not encountered, five patients had cylindruria or hematuria which was accompanied in two cases by a slight rise in serum creatinine. Furthermore, the precise meaning of cylindruria in acid urine is unclear. Transient vestibular abnormalities were seen in two of 34 episodes of treatment. Hematologic or hepatic abnormalities were not encountered.

Zusammenfassung

Sisomicin, ein dehydriertes Gentamicin C1a-Derivat, wurde zur Behandlung schwerer gramnegativer Infektionen eingesetzt. Bei 79 % von 34 Infektionen wurden zufriedenstellende klinische Erfolge erzielt. Unter der Behandlung konnten sogar bei Fällen mit bereits bestehender Nieren- oder Lebererkrankung und trotz gleichzeitiger Gabe von Immunosuppressiva gute Erfolge verzeichnet werden. Harnwegsinfektionen, die durch Pseudomonas oder Serratia hervorgerufen wurden, sprachen ebenfalls gut an, außer bei Patienten mit deutlich ausgeprägten Anomalien. Bei Infektionen der Lunge waren die klinischen Ergebnisse gut, auch wenn bei ausgedehntem Grundleiden der Lunge die Keime nicht aus dem Sputum eliminiert werden konnten. Obwohl keine ernsthafte Nephrotoxizität auftrat, zeigen fünf Patienten Zylindrurie oder Hämaturie, die in zwei Fällen mit einem leichten Anstieg des Serumkreatinin einherging. Allerdings ist die genaue Bedeutung der Zylindrurie im sauren Harn noch unklar. Vorübergehende vestibuläre Störungen wurden bei zwei von 34 Behandlungen beobachtet. Es traten keine Blutbildungs- oder Leberstörungen auf.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Literature

  1. Myerowitz, R. L., Medeiros, A. A., O'Brien, T. F. Recent experience with bacillemia due to gram-negative organisms. J. infect. Dis. 124 (1971) 239–246.

    Google Scholar 

  2. Stewart, D., Bodey, G. P. In vitro activity of sisomicin, an aminoglycoside antibiotic, against clinical isolates. J. Antibiot. 28 (1975) 149–155.

    Google Scholar 

  3. Levison, M. E., Kaye, D. In vitro comparison of four aminoglycoside antibiotics, sisomicin, gentamicin, tobramycin and BB-K 8. Antimicrob. Ag. Chemother. 5 (1974) 667–669.

    Google Scholar 

  4. Bauer, A. W., Kirby, W. M. M., Sherris, J. C., Turck, M. Antibiotic susceptibility testing by a standardized disc method. Amer. J. clin. Path. 45 (1966) 493–496.

    Google Scholar 

  5. Steers, E., Fultz, E. L., Graves, B. S. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot. Chemother. 9 (1959) 307–311.

    Google Scholar 

  6. Welling, P. G., Mosegaard, A., Madsen, P. O. Sisomicin treatment of complicated urinary tract infections: efficacy, tolerance and pharmacokinetics. J. clin. Pharm. 14 (1974) 567–573.

    Google Scholar 

  7. Parry, M. F., Neu, H. C.: Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J. Ped. (1976) in press.

  8. Hawley, H. B., Lewis, R. M., Swartz, D. R., Gump, D. W. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis. Curr. therapy. Res. 16 (1974) 414–423.

    Google Scholar 

  9. Hewitt, W. L. Gentamicin: Toxicity in perspective. Postgrad. Med. 50 Suppl. 1 (1974) 55–59.

    Google Scholar 

  10. Dahlgren, J. G., Anderson, E. T., Hewitt, W. L. Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob. Ag. Chemother. 8 (1975) 58–62.

    Google Scholar 

  11. Luft, F. C., Patel, V., Yum, M. N., Patel, B., Kleit, S. A. Experimental aminoglycoside nephrotoxicity. J. Lab. clin. Med. 86 (1975) 213–220.

    Google Scholar 

  12. Boston Collaborative Drug Surveillance Program: Drug-induced deafness. J. Ama. med. An. 224 (1973) 515–516.

    Google Scholar 

  13. Jackson, G. G., Arcieri, G. Ototoxicity of gentamicin in man: A survey and controlled analysis of clinical experience in the United States. J. infect. Dis. 124S (1971) 130–137.

    Google Scholar 

  14. Wersall, J., Lundquist, P. G., Bjorkroth, B. Ototoxicity of gentamicin. J. infect. Dis. 119S (1969) 410–416.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parry, M., Neu, H., Garvey, G. et al. Sisomicin therapy of serious gram-negative infections. Infection 4 (Suppl 4), S439–S445 (1976). https://doi.org/10.1007/BF01646980

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01646980

Keywords

Navigation